Clinical Efficacy and Safety of Primary Thrombotic Complications Prevention after Orthopaedic Operations

Cover Page


Cite item

Full Text

Abstract

Comparative study of clinical efficacy and safety of dabigatran etexilate (DE) and other widely used anticoagulants (AC) in primary thromboprophylaxis after orthopedic interventions was performed. Retrospectively 828 patients from 13 hospitals located in 10 different Russian towns were evaluated. Seven hundred sixty one patients (91,9%) underwent total arthroplasty of either knee or hip joints and 67 patients — other orthopedic operations. Clinical efficacy of AC was evaluated by the rate of postoperative vein thrombosis, safety of AC — by the rate of postoperative bleedings. No statistically significant difference in the incidence of venous thromboembolism at DE and other AC intake after total arthroplasty (distal thrombosis — 4% [2%, 7%] and 4% [2%, 6%] in DE and other AC subgroups, respectively; proximal thrombosis — 0% [0%, 1%>] in both subgroups and after other orthopaedic interventions (distal thrombosis — 4% [0%, 18%] and 3% [0%, 13%]; proximal thrombosis — 4% [0%, 18%] and [0%, 9%] in DE and other AC subgroups, respectively) was detected. The incidence of bleeding after arthroplasty also showed no significant difference between DE and other AC (minimum postoperative bleeding was 1% and 1% in DE and other AC subgroups, respectively; massive bleeding — 0% in both subgroups. No postoperative bleeding was observed after other orthopaedic interventions. Thus clinical efficacy and safety of DE is comparable to other widely used AC for thrombosis prevention.

Full Text

Клиническая эффективность и безопасность первичной профилактики тромботических осложнений после ортопедических операций
×

References

  1. Загородний Н.В. Профилактика тромбоэмболических осложнений у ортопедических больных при эндопро- тезировании крупных суставов; Российский государственный медицинский университет и Департамент Здравоохранения города Москвы; симпозиум «Профилактика тромбоэмболических осложнений в травматологии и ортопедии». М.; 2002: 34-40.
  2. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(suppl): 381-453.
  3. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell CW, Ray J.G. et al. Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126 (3 Suppl): 338-400.
  4. Testroote M., Stigter W, de Visser D.C., Janzing H. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev. 2008; (4): CD006681.
  5. Samama C.M., Clergue F., Barre J. Montefiore A., Ill P., Samii K. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Br. J. Anaesth. 1997; 78 (6): 660-665.
  6. Mismetti P., Laporte S, Zufferey P., Epinat M., Decousus H., Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a metaanalysis. J. Thromb. Haemost. 2004;.2 (7): 1058-1070.
  7. Francis CW, Pellegrini V.D. Jr, Marder V.J. Totterman S., Harris C.M., Gabriel K.R. et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992; 267 (21): 2911-2915.
  8. Nicolaides A.N., Fareed J., Kakkar A.K., Breddin H.K., Goldhaber S.Z., Hull R. et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int. Angiol. 2006;.25 (2): 101-161.
  9. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010; Т. 4, Вып. 2.
  10. Friedman R.J., Gallus A.S., Cushner F.D., Fitzgerald G., Anderson F.A. Jr et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr. Med. Res. Opin. 2008; 24 (1): 87-97.
  11. Pellegrini V.D. Jr, Donaldson C.T., Farber D.C., Lehman E.B., Evarts C.M. The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin. Orthop. Relat. Res. 2006; 452: 21-7.
  12. Januel J.M., Chen G., Ruffieux C., Quan H., Douketis J.D., Crowther M.A. et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA. 2012; 307 (3): 294-303.
  13. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and kneearthroplasty differ: what are the implications for clinicians and patients? Chest. 2009; 135 (2): 513-20.
  14. Eriksson B., Dahl O., Rosencher N. Kurth A.A., van Dijk C.N., Frostick S.P. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591): 949-956.
  15. Eriksson B., Dahl O., Rosencher N. Kurth A.A., van Dijk C.N., Frostick S.P. et al. Oral dabigatranetexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J. Thromb. Haemost. 2007; 5 (11): 2178-2185.
  16. Eriksson B., Friedman R. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin. Appl. Thromb. Hemost. 2009; 15, Suppl 1: 25-31.
  17. Приказ Министерства здравоохранения и социального развития Российской Федерации (Минздравсоц- развития России) от 31 декабря 2010 г. N 1248н г. Москва. «О порядке формирования и утверждении государственного задания на оказание в 2011 году высокотехнологичной медицинской помощи гражданам Российской Федерации за счет бюджетных ассигнований федерального бюджета». Приложение 3. URL:http://www.minzdravsoc.ru/docs/mzsr/orders/ 1155
  18. Российский консенсус «Профилактика послеоперационных венозных тромбоэмболических осложнений». М., 2000.
  19. Протокол ведения больных. Профилактика тромбоэмболии легочной артерии при хирургических и иных инвазивных вмешательствах. Приложение к приказу Минздрава России от 09.06.2003 г. N 233.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-76249 от 19.07.2019.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies